|Share this content:|
|Home||About Us||Our Attorneys||Cases||Practice Areas||Settlement Notices||News & Events||Contact Us|
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Affymax, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Affymax, Inc. (“Affymax” or the “Company”) (NASDAQ: AFFY).
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) 2% of patients taking Affymax’s kidney treatment drug Omontys were experiencing hypersensitivity reactions resulting in anaphylaxis, a serious and life-threatening allergic reaction; and (2) 0.02% of those taking Omontys experienced fatal anaphylaxis reactions.
On February 23, 2013, Affymax announced that the U.S. Food and Drug Administration (“FDA”) was requiring a total recall of the drug due to reports of anaphylaxis. According to the FDA, “serious and fatal” hypersensitivity reactions had been reported in some patients within 30 minutes of receiving their first doses of the drug by intravenous injection. On this news, the price of Affymax stock declined by more than 85%, closing at $2.42 per share, down $14.10 per share from the prior night’s close.
If you invested in Affymax stock or options between December 8, 2011 and February 22, 2013 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org or email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Affymax’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you. If you want to be a Lead Plaintiff or join
this action now, please click HERE.